Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MIRA Pharmaceuticals, Inc. (MIRA)
USD0.94
+0.03 (+3.76%)
US NASDAQ Healthcare Drug Manufacturers - General
Address
855 North Wolfe Street 21205
Baltimore, MD, US
Baltimore, MD, US
CEO
Erez Aminov
Website
mirapharmaceuticals.com
IPO
2023-08-14
CIK 1904286 ISIN US60458C1045
Description
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.94
+0.03 (+3.76%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
122.2K
Beta
1.49
Float Shares
26.86M
Free Float %
63.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -3.46% | -7.13% | -15.94% | -29.34% | -35.42% | -26.68% | -84.81% | -84.81% | -84.81% | -84.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.94
DCF (Unlevered)
0.27
-71.6%
DCF (Levered)
0.27
-71.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
207.50
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%—
-
EPS growth Drug Manufacturers - General: +18.2%-164.7% Q1'26: +72.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%—
-
EBIT margin Drug Manufacturers - General: +19.4%—
-
ROIC Drug Manufacturers - General: +10.2%-259.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+53.4% Q1'26: +152.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.00×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
—
|
—
|
276.00M
276.00M – 276.00M
|
40.00M
40.00M – 40.00M
-85.5% YoY
|
| EBITDA |
-8.02M
|
-10.49M
|
—
— – —
|
—
— – —
|
| EBIT |
-8.02M
|
-10.49M
|
—
— – —
|
—
— – —
|
| Net Income |
-7.85M
est: -8.55M (+8.1%)
|
-10.44M
est: -27.72M (+62.3%)
|
-4.26M
-4.26M – -4.26M
+84.6% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
4.71M
|
8.77M
|
—
— – —
|
—
— – —
|
| EPS |
-0.51
est: -0.55 (+7.8%)
|
-1.35
est: -1.17 (-15.4%)
|
-0.18
-0.18 – -0.18
+84.6% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
15
Total invested
1.62M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
15
-10 vs prev Q
New positions
5
Closed positions
15
Increased
7
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 660.5K +456.9K (+224.3%) | 997.4K +720.4K (+260.1%) | 3.43% +2.228 pp | 0.00% +0.000 pp | USD1.42 +6.3% | 5 qtrs — |
| 2 | CROSS STAFF INVESTMENTS INC | 359.4K +— (+0.0%) | 542.7K +53.9K (+11.0%) | 1.86% -0.251 pp | 0.30% -0.042 pp | USD1.08 +39.8% | 8 qtrs — |
| 3 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 312.8K +312.8K (+100.0%) | 472.3K +472.3K (+100.0%) | 1.62% +1.623 pp | 0.00% +0.001 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 272.9K +136.4K (+100.0%) | 412.0K +226.5K (+122.1%) | 1.42% +0.613 pp | 0.00% +0.000 pp | USD1.39 +8.6% | 6 qtrs — |
| 5 | BLACKROCK, INC. | 109.8K +— (+0.0%) | 165.8K +16.5K (+11.0%) | 0.57% -0.077 pp | 0.00% +0.000 pp | USD1.36 +11.0% | 2 qtrs — |
| 6 | SUNCOAST EQUITY MANAGEMENT | 103.3K +— (+0.0%) | 156.0K +15.5K (+11.0%) | 0.54% -0.072 pp | 0.02% +0.002 pp | USD1.03 +46.6% | 8 qtrs — |
| 7 | NORTHERN TRUST CORP | 67.7K +24.0K (+54.8%) | 102.2K +42.7K (+71.9%) | 0.35% +0.094 pp | 0.00% +0.000 pp | USD1.36 +11.0% | 9 qtrs — |
| 8 | FIRST AMERICAN BANK | 60.0K +10.0K (+20.0%) | 90.6K +22.6K (+33.2%) | 0.31% +0.017 pp | 0.01% +0.001 pp | USD1.29 +17.1% | 8 qtrs — |
| 9 | STATE STREET CORP | 49.1K +— (+0.0%) | 74.1K +7.4K (+11.0%) | 0.25% -0.034 pp | 0.00% +0.000 pp | USD1.14 +32.5% | 5 qtrs — |
| 10 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 35.0K +— (+0.0%) | 52.9K +10.5K (+24.8%) | 0.18% -0.025 pp | 0.00% +0.000 pp | USD1.21 +24.8% | 5 qtrs — |
| 11 | COMMONWEALTH EQUITY SERVICES, LLC | 30.2K +— (+0.0%) | 45.6K +4.6K (+11.2%) | 0.16% -0.021 pp | 0.00% +0.000 pp | USD1.10 +37.3% | 5 qtrs — |
| 12 | TWO SIGMA INVESTMENTS, LP | 27.0K -18.7K (-40.8%) | 40.8K -21.3K (-34.3%) | 0.14% -0.129 pp | 0.00% +0.000 pp | USD1.26 +19.8% | 5 qtrs — |
| 13 | CREATIVE PLANNING | 22.6K +— (+0.0%) | 34.1K +3.4K (+11.0%) | 0.12% -0.016 pp | 0.00% +0.000 pp | USD1.21 +24.8% | 3 qtrs — |
| 14 | AQR CAPITAL MANAGEMENT LLC | 22.0K +— (+0.0%) | 33.2K +3.3K (+11.0%) | 0.11% -0.015 pp | 0.00% +0.000 pp | USD1.36 +11.0% | 2 qtrs — |
| 15 | XTX TOPCO LTD | 20.9K -15.0K (-41.8%) | 31.6K -17.3K (-35.4%) | 0.11% -0.103 pp | 0.00% -0.002 pp | USD1.27 +18.9% | 3 qtrs — |
| 16 | FIFTH THIRD BANCORP | 20.0K +20.0K (+100.0%) | 30.2K +30.2K (+100.0%) | 0.10% +0.104 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 17 | MARINER, LLC | 16.5K +— (+0.0%) | 24.9K +2.5K (+11.0%) | 0.09% -0.012 pp | 0.00% +0.000 pp | USD1.16 +30.2% | 5 qtrs — |
| 18 | CARY STREET PARTNERS FINANCIAL LLC | 10.0K +— (+0.0%) | 15.1K +1.5K (+11.0%) | 0.05% -0.007 pp | 0.00% +0.000 pp | USD1.14 +32.5% | 5 qtrs — |
| 19 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 8.0K +1.0K (+14.3%) | 12.1K +2.6K (+26.9%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD1.38 +9.4% | 2 qtrs — |
| 20 | UBS GROUP AG | 2.7K +2.5K (+1,150.0%) | 4.1K +3.8K (+1,286.7%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD1.49 +1.3% | 3 qtrs — |
| 21 | ADVISOR GROUP HOLDINGS, INC. | 2.0K +— (+0.0%) | 3.0K +280.0 (+10.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.14 +32.5% | 5 qtrs — |
| 22 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 2.0K +— (+0.0%) | 3.0K +300.0 (+11.0%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.22 +23.8% | 6 qtrs — |
| 23 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.8K +33.0 (+1.8%) | 2.8K +319.0 (+13.1%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.36 +11.0% | 2 qtrs — |
| 24 | BANK OF AMERICA CORP /DE/ | 261.00 +121.0 (+86.4%) | 395.00 +205.0 (+107.9%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.32 +14.4% | 6 qtrs — |
| 25 | WELLS FARGO & COMPANY/MN | 23.00 +— (+0.0%) | 35.00 +4.0 (+12.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.35 +11.9% | 2 qtrs — |
| 26 | CITIGROUP INC | — -3.8K (-100.0%) | — -5.2K (-100.0%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 27 | J.W. COLE ADVISORS, INC. | — -45.5K (-100.0%) | — -61.9K (-100.0%) | 0.00% -0.268 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
| 28 | RENAISSANCE TECHNOLOGIES LLC | — -46.7K (-100.0%) | — -63.5K (-100.0%) | 0.00% -0.275 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 29 | EVERSOURCE WEALTH ADVISORS, LLC | — -365.0 (-100.0%) | — -496.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 30 | FMR LLC | — -115.0 (-100.0%) | — -156.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 31 | VIRTU FINANCIAL LLC | — -12.2K (-100.0%) | — -17.0K (-100.0%) | 0.00% -0.072 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 117.1K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 368.3K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 757.51 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.1K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 153.63 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 355.4K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 778.74 | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 423.70 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 171.17 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 18.88 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
83.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+83,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | Aminov Erez | Director / Officer | A-Award | A | Restricted Stock Units | 83,500 | 0.00 | — | 83,500 | D | ↗ |
| 2025-12-17 | Aminov Erez | Director / Officer | A-Award | A | Stock Options (right to buy) | 3,155,170 | 1.45 | 4.57M | 3,155,170 | D | ↗ |
| 2025-10-16 | Aminov Erez | Director / Officer | M-Exempt | A | Stock Options (right to buy) | 379,000 | 0.84 | 318.4K | 379,000 | D | ↗ |
| 2025-10-01 | Shekhat Denil Nanji | Director | A-Award | A | Common Stock | 22,378 | 1.35 | 30.2K | 22,378 | D | ↗ |
| 2025-10-01 | Aminov Erez | Director / Officer | A-Award | A | Common Stock | 2,685,456 | 0.00 | — | 3,530,156 | D | ↗ |
| 2025-09-18 | Aminov Erez | Director / Officer | A-Award | A | Stock Options (right to buy) | 150,000 | 1.38 | 207.0K | 150,000 | D | ↗ |
| 2025-08-29 | Aminov Erez | Director / Officer | A-Award | A | Common Stock | 62,500 | 1.37 | 85.6K | 844,700 | D | ↗ |
| 2025-05-15 | Weichselbaum Alan | Officer | — | — | Stock Options (right to buy) | 75,000 | 1.18 | 88.5K | 0 | D | ↗ |
| 2024-12-09 | Yanez Michelle | Officer | A-Award | A | Stock Options (right to buy) | 150,000 | 1.19 | 178.5K | 150,000 | D | ↗ |
| 2024-12-09 | Whalen Matthew Pratt | Director | A-Award | A | Stock Options (right to buy) | 25,000 | 1.19 | 29.8K | 25,000 | D | ↗ |
| 2024-12-09 | Shekhat Denil Nanji | Director | A-Award | A | Stock Options (right to buy) | 50,000 | 1.19 | 59.5K | 50,000 | D | ↗ |
| 2024-12-09 | MacPherson Edward Clouston | Director | A-Award | A | Stock Options (right to buy) | 25,000 | 1.19 | 29.8K | 25,000 | D | ↗ |
| 2024-12-09 | Del Giudice Matthew Paul | Director | A-Award | A | Stock Options (right to buy) | 25,000 | 1.19 | 29.8K | 75,000 | D | ↗ |
| 2024-12-09 | Aminov Erez | Director / Officer | A-Award | A | Stock Options (right to buy) | 2,000,000 | 1.19 | 2.38M | 2,000,000 | D | ↗ |
| 2024-11-20 | Aminov Erez | Director / Officer | S-Sale | D | Common Stock | 44,590 | 1.27 | 56.6K | 1,061,200 | D | ↗ |
| 2024-11-19 | Aminov Erez | Director / Officer | S-Sale | D | Common Stock | 55,410 | 1.39 | 77.0K | 1,105,790 | D | ↗ |
| 2024-11-18 | Whalen Matthew Pratt | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-28 | McNulty Brian Patrick | 10% Owner | S-Sale | D | Common Stock | 200,000 | 1.96 | 392.0K | 2,540,270 | — | ↗ |
| 2024-06-18 | Shekhat Denil Nanji | Director | A-Award | A | Nonqualified Stock Option (right to buy) | 50,000 | 0.71 | 35.5K | 41,666 | — | ↗ |
| 2024-05-28 | Aminov Erez | Director / Officer | A-Award | A | Incentive Stock Options (right to buy) | 379,000 | 0.84 | 318.4K | 629,000 | — | ↗ |
| 2024-05-21 | Aminov Erez | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 1.00 | 2.0K | 375,500 | — | ↗ |
| 2024-03-26 | Yanez Michelle | Officer | A-Award | A | Incentive Stock Option (right to buy) | 150,000 | 1.15 | 172.5K | 57,799 | — | ↗ |
| 2024-03-26 | Aminov Erez | Director / Officer | A-Award | A | Incentive Stock Option (right to buy) | 300,000 | 1.15 | 345.0K | 250,000 | — | ↗ |
| 2024-03-25 | Shekhat Denil Nanji | Director | A-Award | A | Nonqualified Stock Option (right to buy) | 50,000 | 1.16 | 58.0K | 25,000 | — | ↗ |
| 2024-03-25 | MacPherson Edward Clouston | Director | A-Award | A | Nonqualified Stock Option (right to buy) | 50,000 | 1.16 | 58.0K | 25,000 | — | ↗ |
| 2024-03-25 | Jerman Michael Allen | Director | A-Award | A | Nonqualified Stock Option (right to buy) | 50,000 | 1.16 | 58.0K | 25,000 | — | ↗ |
| 2024-03-25 | Del Giudice Matthew Paul | Director | A-Award | A | Nonqualified Stock Option (right to buy) | 50,000 | 1.16 | 58.0K | 25,000 | — | ↗ |
| 2024-03-13 | Shekhat Denil Nanji | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-13 | MacPherson Edward Clouston | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-13 | Del Giudice Matthew Paul | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-02 | Vorhoff David C | Director | — | D | Common Stock | 0 | 0.00 | — | 40,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
42.02M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Erez Aminov, CEO | 83.3K | 208.0K | — | 1.37M | — | 5.6K | 1.67M | 82.17% | ↗ |
| 2 | 2023 | Michelle Yanez, CFO | 165.0K | 88.5K | — | 282.2K | — | 5.9K | 541.6K | 52.11% | ↗ |
| 3 | 2023 | Adam Kaplin, former President & CSO | 50.0K | — | — | 149.6K | — | — | 199.6K | 74.95% | ↗ |
| 4 | 2023 | Jim McNulty, former CFO | 154.0K | — | — | — | — | — | 154.0K | 0.00% | ↗ |
| 5 | 2023 | Jude Uzonwanne, former CEO | 75.0K | — | — | — | — | 6.6K | 81.6K | 0.00% | ↗ |
| 6 | 2022 | Jude Uzonwanne, former CEO | 125.0K | 50.0K | — | 739.0K | — | 8.4K | 922.4K | 80.12% | ↗ |
| 7 | 2022 | Adam Kaplin, former President & CSO | — | 50.0K | — | 739.0K | — | — | 789.0K | 93.66% | ↗ |
| 8 | 2022 | Jim McNulty, former CFO | 266.9K | 100.0K | — | — | — | — | 366.9K | 0.00% | ↗ |
| 9 | 2022 | Michelle Yanez, CFO | 110.0K | — | — | 37.0K | — | 6.1K | 153.0K | 24.15% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erez Aminov | Chief Executive Officer & Chairman | 700.7K | male |
| Alan Weichselbaum | CFO & Treasurer | 59.8K | male |
| Itzchak Angel | Chief Scientific Advisor | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - GENERAL
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MIRA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
